Franklin Street Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Franklin Street Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-20,447	Closed	-$1.63M	–	220
2016 Q1	$1.63M	Buy	20,447 +8,877	+77%	+$803K	0.32%	79
2015 Q4	$1.46M	Sell	11,570 -870	-7%	-$105K	0.29%	97
2015 Q3	$1.3M	Sell	12,440 -300	-2%	-$38.5K	0.26%	99
2015 Q2	$1.57M	Sell	12,740 -1,920	-13%	-$242K	0.28%	93
2015 Q1	$1.73M	Sell	14,660 -8,645	-37%	-$1.04M	0.32%	87
2014 Q4	$2.77M	Buy	23,305 +470	+2%	+$52.9K	0.53%	62
2014 Q3	$2.56M	Hold	22,835	–	–	0.49%	59
2014 Q2	$2.16M	Sell	22,835 -13,000	-36%	-$912K	0.41%	70
2014 Q1	$2.53M	Hold	35,835	–	–	0.51%	57
2013 Q4	$2.66M	Buy	+35,835	New	+$2.5M	0.54%	54

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Street Advisors's VRTX Position: Q2 2016 in Review

Franklin Street Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 20,447 shares — an estimated $1.63M sold.

Franklin Street Advisors first reported a position in VRTX in Q4 2013 and held it in 10 quarters. The position peaked at $2.77M in Q4 2014. 483 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

Franklin Street Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Franklin Street Advisors sold 20,447 Vertex Pharmaceuticals shares in Q2 2016, an estimated $1.63M.
Franklin Street Advisors first reported a position in Vertex Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Franklin Street Advisors's Vertex Pharmaceuticals position peaked at $2.77M in Q4 2014.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Franklin Street Advisors's 13F filing for Q2 2016, filed 11 Jul 2016.